NDAORALCAPSULE
Approved
Sep 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIBRAX is a fixed-dose oral combination of chlordiazepoxide (a benzodiazepine) and clidinium bromide (an anticholinergic) approved in 1966 for gastrointestinal disorders. It is indicated for adjunctive treatment of peptic ulcer disease and irritable bowel syndrome by reducing anxiety and gastrointestinal motility. The combination works synergistically to address both the psychological and physiological components of functional bowel disorders.
$3MPart D
LOE ApproachingDeclining
Minimal commercial momentum with declining Part D spending signals a mature, niche product experiencing erosion; brand team likely small and focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
Started May 2011
21 enrolled
Parkinson's Disease
Career Relevance
LIBRAX offers minimal career opportunity within modern pharma; the product generates negligible linked job postings and operates in a mature, declining commercial landscape with no clinical development. Roles on this asset would be small, defensive, and centered on maintaining legacy market share in a shrinking niche.
Brand Manager (if role exists)
Worked on LIBRAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.